Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13371MR)

This product GTTS-WQ13371MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13371MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13597MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ15016MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ1157MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ13007MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ3687MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ2783MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ10244MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ3153MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APT070
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW